Cargando…

De Novo Design of an Androgen Receptor DNA Binding Domain‐Targeted peptide PROTAC for Prostate Cancer Therapy

Androgen receptor splice variant‐7 (AR‐V7), one of the major driving factors, is the most attractive drug target in castration‐resistant prostate cancer (CRPC). Currently, no available drugs efficiently target AR‐V7 in clinical practice. The DNA binding domain (DBD) is indispensable for the transcri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Bohan, Fan, Yizeng, Zhang, Dize, Wei, Yi, Jian, Yanlin, Liu, Donghua, Wang, Zixi, Gao, Yang, Ma, Jian, Chen, Yule, Xu, Shan, Li, Lei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9534960/ https://www.ncbi.nlm.nih.gov/pubmed/35971165 http://dx.doi.org/10.1002/advs.202201859

Ejemplares similares

Design of stapled peptide-based PROTACs for MDM2/MDMX atypical degradation and tumor suppression
por: Chen, Si, et al.
Publicado: (2022)

Estrogen Receptor-α Targeting: PROTACs, SNIPERs, Peptide-PROTACs, Antibody Conjugated PROTACs and SNIPERs
por: Negi, Arvind, et al.
Publicado: (2022)

PROTAC-DB: an online database of PROTACs
por: Weng, Gaoqi, et al.
Publicado: (2020)

PROTACs in the Management of Prostate Cancer
por: Yedla, Poornachandra, et al.
Publicado: (2023)

Chemical Degradation of Androgen Receptor (AR) Using Bicalutamide Analog–Thalidomide PROTACs
por: Kim, Ga Yeong, et al.
Publicado: (2021)

Non-small molecule PROTACs (NSM-PROTACs): Protein degradation kaleidoscope
por: Ma, Sinan, et al.
Publicado: (2022)

RNA‐PROTACs: Degraders of RNA‐Binding Proteins
por: Ghidini, Alice, et al.
Publicado: (2020)

The PROTAC technology in drug development
por: Zou, Yutian, et al.
Publicado: (2019)

DeepPROTACs is a deep learning-based targeted degradation predictor for PROTACs
por: Li, Fenglei, et al.
Publicado: (2022)

Specific MHC-I Peptides Are Induced Using PROTACs
por: Jensen, Stephanie M., et al.
Publicado: (2018)

Destruction of DNA‐Binding Proteins by Programmable Oligonucleotide PROTAC (O'PROTAC): Effective Targeting of LEF1 and ERG
por: Shao, Jingwei, et al.
Publicado: (2021)

EZH2-regulated immune risk score prognostic model predicts outcome of clear cell renal cell carcinoma
por: Xu, Shan, et al.
Publicado: (2023)

PROTAC-DB 2.0: an updated database of PROTACs
por: Weng, Gaoqi, et al.
Publicado: (2022)

In Silico Tools to Extract the Drug Design Information Content of Degradation Data: The Case of PROTACs Targeting the Androgen Receptor
por: Apprato, Giulia, et al.
Publicado: (2023)

Light-induced control of protein destruction by opto-PROTAC
por: Liu, Jing, et al.
Publicado: (2020)

Clinical considerations for the design of PROTACs in cancer
por: Nieto-Jiménez, Cristina, et al.
Publicado: (2022)

Are we ready to design oral PROTACs®?
por: Jimenez, Diego Garcia, et al.
Publicado: (2021)

A narrative review of proteolytic targeting chimeras (PROTACs): future perspective for prostate cancer therapy
por: Chen, Xuanrong, et al.
Publicado: (2021)

Design and Characterization of SGK3-PROTAC1, an Isoform Specific SGK3 Kinase PROTAC Degrader
por: Tovell, Hannah, et al.
Publicado: (2019)

TRABID overexpression enables synthetic lethality to PARP inhibitor via prolonging 53BP1 retention at double-strand breaks
por: Ma, Jian, et al.
Publicado: (2023)

The peptide PROTAC modality: a novel strategy for targeted protein ubiquitination
por: Jin, Jinmei, et al.
Publicado: (2020)

PROTACs in gastrointestinal cancers
por: Chen, Yu, et al.
Publicado: (2022)

Structure‐Based Design of a Macrocyclic PROTAC
por: Testa, Andrea, et al.
Publicado: (2019)

Novel approaches for the rational design of PROTAC linkers
por: Zagidullin, Almaz, et al.
Publicado: (2020)

Designing Soluble PROTACs: Strategies and Preliminary Guidelines
por: García Jiménez, Diego, et al.
Publicado: (2022)

A cell-permeable peptide-based PROTAC against the oncoprotein CREPT proficiently inhibits pancreatic cancer
por: Ma, Danhui, et al.
Publicado: (2020)

Recent Advances of Degradation Technologies Based on PROTAC Mechanism
por: Xiao, Mingchao, et al.
Publicado: (2022)

Structure of the homodimeric androgen receptor ligand-binding domain
por: Nadal, Marta, et al.
Publicado: (2017)

Pan-cancer analysis reveals the prognostic and immunologic roles of cereblon and its significance for PROTAC design
por: Zhang, Si-Han, et al.
Publicado: (2023)

OR35-02 Novel Androgen Receptor PROTAC Degrader ARV-110 Ameliorates Androgen Mediated Renal Injury in a Mouse Model of Polycystic Ovary Syndrome
por: Basnet, Jelina, et al.
Publicado: (2023)

PROTACs: The Future of Leukemia Therapeutics
por: Anwar, Zubair, et al.
Publicado: (2022)

Light-mediated multi-target protein degradation using arylazopyrazole photoswitchable PROTACs (AP-PROTACs)
por: Zhang, Qisi, et al.
Publicado: (2022)

De novo design of modular peptide-binding proteins by superhelical matching
por: Wu, Kejia, et al.
Publicado: (2023)

De novo design of a stapled peptide targeting SARS-CoV-2 spike protein receptor-binding domain
por: Thakkar, Ravindra, et al.
Publicado: (2023)

An overview of PROTACs: a promising drug discovery paradigm
por: Liu, Zi, et al.
Publicado: (2022)

TET2 binds the androgen receptor and loss is associated with prostate cancer
por: Nickerson, ML, et al.
Publicado: (2016)

Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer
por: Zadra, Giorgia, et al.
Publicado: (2019)

PROTACs– a game-changing technology
por: Konstantinidou, Markella, et al.
Publicado: (2019)

Degradation of proteins by PROTACs and other strategies
por: Wang, Yang, et al.
Publicado: (2020)

PROTACs: great opportunities for academia and industry
por: Sun, Xiuyun, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_h06p1c92a0ilnso3kip5f8muj6